舒泰神股价连续3天下跌累计跌幅6.81%，广发基金旗下1只基金持23.57万股，浮亏损失57.98万元

Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is located in Beijing Economic and Technological Development Zone, established on August 16, 2002, and listed on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1]. Financial Performance - As of September 29, Shuyou Shen's stock price fell by 0.65% to 33.65 CNY per share, with a trading volume of 479 million CNY and a turnover rate of 3.16%. The total market capitalization is 16.077 billion CNY. The stock has experienced a cumulative decline of 6.81% over the past three days [1]. - The main revenue sources for Shuyou Shen are: 59.17% from injectable mouse nerve growth factor (Sutai Shen), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1]. Fund Holdings - According to data from the top ten heavy stocks of funds, one fund under GF Fund holds Shuyou Shen as a significant position. The GF Hong Kong-Shenzhen Medical Mixed A Fund (014114) held 235,700 shares in the second quarter, accounting for 2.86% of the fund's net value, ranking as the tenth largest holding. The estimated floating loss today is approximately 51,900 CNY, with a total floating loss of 579,800 CNY during the three-day decline [2]. - The GF Hong Kong-Shenzhen Medical Mixed A Fund was established on December 29, 2021, with a current scale of 204 million CNY. Year-to-date returns are 76.81%, ranking 223 out of 8,244 in its category; the one-year return is 84.5%, ranking 709 out of 8,080; and since inception, the return is 14.5% [2]. Fund Management - The fund manager of GF Hong Kong-Shenzhen Medical Mixed A Fund is Wu Xingwu, who has been in the position for 10 years and 233 days. The total asset size of the fund is 9.853 billion CNY, with the best fund return during his tenure being 112.41% and the worst being -33.74% [3].